India introduces Qartemi a groundbreaking CAR-T cell therapy to fight advanced blood cancers like B-cell Non-Hodgkin Lymphoma ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

The Brunswick For a Brighter Future Student Visionaries have set a $100,000 fundraising goal in 2025 as it raises money for ...

The facility of bone marrow transplant is not available for the treatment of thalassemia, aplastic anaemia, and blood cancer ...

In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a ...

An emotional two-year journey reached a heart-warming milestone as Newark’s miracle boy, who defied all the odds to ring his ...

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Researchers from the University of Pittsburgh have developed a new way to grow T cells in the lab that enables them to live longer and better destroy cancer cells in a mouse model of melanoma compared ...

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

Jeffrey V. Matous, MD, discusses how best practices in transitioning care between academic and community centers can enhance patient outcomes when receiving bispecific antibodies, and the critical ...